- Home
- TVTX
as of 03-04-2026 10:09am EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.3B | IPO Year: | 2013 |
| Target Price: | $36.85 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | 92.89 |
| 52 Week Low/High: | $12.91 - $42.13 | Next Earning Date: | 05-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 44.75% | Revenue Growth (next year): | 26.82% |
| P/E Ratio: | -97.69 | Index: | N/A |
| Free Cash Flow: | 37.1M | FCF Growth: | N/A |
AI-Powered TVTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$30.10
Shares
60,000
Total Value
$1,805,766.00
Owned After
432,886
SEC Form 4
Chief Legal Officer and GC
Avg Cost/Share
$27.88
Shares
10,000
Total Value
$278,315.32
Owned After
109,532
Chief Legal Officer and GC
Avg Cost/Share
$32.41
Shares
2,994
Total Value
$96,358.61
Owned After
109,532
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$32.52
Shares
1,745
Total Value
$56,167.90
Owned After
111,336
CHIEF MEDICAL OFFICER
Avg Cost/Share
$32.48
Shares
1,779
Total Value
$57,295.37
Owned After
105,706
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$32.38
Shares
100,087
Total Value
$3,230,315.62
Owned After
432,886
Chief Research Officer
Avg Cost/Share
$32.87
Shares
12,446
Total Value
$409,100.02
Owned After
109,087
SEC Form 4
SVP, CHIEF ACCOUNTING OFFICER
Avg Cost/Share
$32.12
Shares
4,333
Total Value
$139,175.96
Owned After
49,080
SEC Form 4
Chief Legal Officer and GC
Avg Cost/Share
$32.12
Shares
7,175
Total Value
$230,461.00
Owned After
109,532
SEC Form 4
CHIEF COMMERCIAL OFFICER
Avg Cost/Share
$32.12
Shares
7,310
Total Value
$234,797.20
Owned After
131,823
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Feb 20, 2026 | Sell | $30.10 | 60,000 | $1,805,766.00 | 432,886 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Feb 17, 2026 | Sell | $27.88 | 10,000 | $278,315.32 | 109,532 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Feb 4, 2026 | Sell | $32.41 | 2,994 | $96,358.61 | 109,532 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Sell | $32.52 | 1,745 | $56,167.90 | 111,336 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Feb 4, 2026 | Sell | $32.48 | 1,779 | $57,295.37 | 105,706 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Feb 3, 2026 | Sell | $32.38 | 100,087 | $3,230,315.62 | 432,886 | |
| ROTE WILLIAM E. | TVTX | Chief Research Officer | Feb 3, 2026 | Sell | $32.87 | 12,446 | $409,100.02 | 109,087 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Feb 3, 2026 | Sell | $32.12 | 4,333 | $139,175.96 | 49,080 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Feb 3, 2026 | Sell | $32.12 | 7,175 | $230,461.00 | 109,532 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Feb 3, 2026 | Sell | $32.12 | 7,310 | $234,797.20 | 131,823 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 19, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 19, 2026 · 100% conf.
1D
-4.52%
$27.97
5D
-9.02%
$26.66
20D
-8.44%
$26.83
tvtx-202602190001438533false00014385332026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026
TRAVERE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-36257 27-4842691
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Address of Principal Executive Offices, including Zip Code)
(888) 969-7879 (Registrant’s Telephone Number, including Area Code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per share TVTXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition. On February 19, 2026, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description 99.1Press release of Travere Therapeutics, Inc. dated February 19, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRAVERE THERAPEUTICS, INC.
Dated: February 19, 2026 By:/s/ Eric Dube Name:Eric Dube Title:Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-4.52%
$27.97
5D
-9.02%
$26.66
20D
-8.44%
$26.83
tvtx-202601120001438533false00014385332026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
TRAVERE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-36257 27-4842691
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Address of Principal Executive Offices, including Zip Code)
(888) 969-7879 (Registrant’s Telephone Number, including Area Code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per share TVTXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description 99.1Press release of Travere Therapeutics, Inc. dated January 12, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRAVERE THERAPEUTICS, INC.
Dated: January 12, 2026 By:/s/ Eric Dube Name:Eric Dube Title:Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
Q3 2025 Earnings
8-KOct 30, 2025
tvtx-202510300001438533false00014385332025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025
TRAVERE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-36257 27-4842691
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Address of Principal Executive Offices, including Zip Code)
(888) 969-7879 (Registrant’s Telephone Number, including Area Code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per share TVTXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition. On October 30, 2025, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description 99.1Press release of Travere Therapeutics, Inc. dated October 30, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRAVERE THERAPEUTICS, INC.
Dated: October 30, 2025 By:/s/ Eric Dube Name:Eric Dube Title:Chief Executive Officer
Compare TVTX vs Leading Stocks
See how TVTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.